Quark Sees Nitto Denko Deal as 'Harbinger' of Future Partnerships

According to a company official, future deals, as with the one with Nitto Denko, will be driven by Quark's freedom to operate in the siRNA drugs space.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.